Summary: A new experimental cancer drug could ease cognitive difficulties for those with Rett syndrome, a rare autism-linked disorder, by enhancing brain cell functions. The drug, ADH-503, improves the activity of microglia, which are crucial for maintaining neural networks.
Researchers found that healthy microglia restored synapse function in brain organoids mimicking Rett syndrome. This breakthrough suggests potential therapies for Rett syndrome and other neurological conditions.
Key Facts:
- ADH-503, an experimental cancer drug, may help cognitive function in Rett syndrome.
- The drug enhances microglia activity, improving synapse function in brain organoids.
- This research could lead to therapies for various neurological conditions.
Source: UCSD
An experimental cancer drug could make thinking easier for individuals with Rett syndrome, a rare disorder linked to autism, according to new research from the University of California San Diego — a discovery that could lead to therapies for patients with other neurological conditions.
The findings, published July 25 in Stem Cell Reports, highlight the role of microglia — a type of white blood cell found in the central nervous system — in the formation of the human brain.
While such cells have been better studied in neurodegenerative disorders like Alzheimer’s disease, amyotrophic lateral sclerosis (ALS) and multiple sclerosis, “very little information has existed on their role in early stages of neural development” because access to fetal tissue is limited, said Pinar Mesci, Ph.D., the study’s lead researcher.
Now employed elsewhere, she completed work on the project while at the university.
In a bid to better understand their function, Mesci instead used brain organoids — “mini brains,” essentially, that mimic the developing brain of an embryo — grown from skin-derived stem cells of consenting patients.
Such organoids were created from individuals with Rett syndrome — a disorder primarily found in females that features loss of speech, purposeful use of hands, mobility and muscle tone, among other symptoms — as well as from neurotypical individuals.
Mesci then added healthy microglia to the Rett syndrome brain organoids and found that the functioning of synapses — where neurons connect and communicate — was “rescued.”
This occurred due to the restoration of phagocytosis, a process by which microglia — sometimes referred to as the “janitors” of the central nervous system — ingest and destroy foreign substances like bacteria and dead cells, keeping the brain and spinal cord tidy. The process also involves “pruning” of synapses, which optimizes brain function.
Researchers also found that the synapses of typical neurons experienced impaired functioning when Rett syndrome microglia were introduced, further confirming the role of the immune cell in brain function and development.
“If the brain’s ‘janitors’ are not working, problems start to arise,” said UC San Diego School of Medicine professor Alysson Muotri, Ph.D., senior author and director of the university’s Sanford Stem Cell Institute’s Integrated Space Stem Cell Orbital Research Center.
Faulty microglia make cognition even harder for Rett syndrome patients, who already contend with fewer and impaired synapses and dysfunctional astrocytes due to a loss of function in the MECP2 gene, implicated in other types of neurodevelopmental conditions as well.
Microglia with loss of MECP2 function “are not as good at pruning synapses and shaping the neural network — they don’t do a good job,” Muotri said.
The team then tested a battery of existing drugs on the microglia, to see if any might restore phagocytosis. They found one: ADH-503, also known as GB1275 — an experimental oral pancreatic cancer medication that also reduces the number of immune-supressing cells that enter a tumor. The drug serves as a regulator of CD11b, a protein involved in phagocytosis, among other processes.
Other studies on Rett syndrome have highlighted potential therapeutic targets. But none so far have identified a potential treatment involving human microglial cells.
By the time Rett syndrome patients are diagnosed, it’s too late to repair and not currently possible to replace faulty neurons, the primary issue in the disease. “But by focusing on other cell types — and potentially finding drugs that improve how they work — we might improve the environment for those neurons and ease functioning for patients,” Mesci said. “That’s what I’m excited about.”
Jonathan Kipnis, Ph.D., professor of pathology, immunology, neurology, neuroscience and neurosurgery at Washington University School of Medicine in St. Louis and director of its Brain Immunology and Glia Center, said the new research “nicely demonstrates” microglia as a potential therapeutic target in Rett syndrome.
“I hope this work will ‘move the needle’ and bring the Rett community back to neuroimmunology,” Kipnis said.
“Understanding neuro-immune interactions in this complex disease may not only provide new insights into the disease biology, but also develop novel approaches to attenuate its progression.”
The research represents the first successful integration of human microglia into Rett syndrome brain tissues in vitro — a model that may prove superior to mouse models.
The researchers hope the study “opens doors for therapies,” not only for those with Rett syndrome, but for those with other neurodevelopmental and neurodegenerative disorders in which microglia play a role.
“That’s my wish,” Mesci said, “that we can improve quality of life.”
Co-authors of the study include Christopher LaRock, with the Department of Pediatrics at the University California San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences; Jacob J. Jeziroski, Natalia Chermount, Tomoka Ozaki, Aurian Saleh, Cedric E. Snethlage, Sandra Sanchez, Gabriela Goldberg, Clever A. Trujillo and Kinichi Nakashima, with the University of California San Diego School of Medicine and Department of Pediatrics at Rady Children’s Hospital San Diego, and the Department of Cellular & Molecular Medicine; Hideyuki Nakashima, with the Department of Stem Cell Biology and Medicine at Kyushu University’s Graduate School of Medicine; Adriano Ferrasa, with the Experimental Multiuser Labratory at the Graduate Program in Health Sciences at the School of Medicine at Pontifícia Universidade Católica do Paraná in Curitiba, Paraná, Brazil, as well as the Department of Informatics at the Universidade Estadual de Ponta Grossa in Ponta Grossa, Parana, Brazil; Roberto H. Herai, with the Experimental Multiuser Labratory at the Graduate Program in Health Sciences at the School of Medicine at Pontifícia Universidade Católica do Paraná in Curitiba, Paraná, Brazil, and the Research Department at Lico Kaesemodel Institute in Curitiba, Paraná, Brazil; and Victor Nizet, with the Department of Pediatrics at the University California San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences.
Funding: This work was made possible in part by the California Institute for Regenerative Medicine (CIRM) Major Facilities grant (FA1-00607) to the Sanford Consortium for Regenerative Medicine. Muotri is supported by the National Institutes of Health (NIH) R01MH107367, R01HD107788, R01NS105969 and R01NS123642, and a grant from the International Rett Syndrome Foundation (IRSF).
This work was also partially funded by the IRSF Innovation Award granted to Mesci (grant No. 3905).
Herai is funded by Fundação Araucária (grant No. FA09/2016). This work was also partially funded by AMED (JP22mg1310008), an Intramural Research Grant (3-9) for Neurological and Psychiatric Disorders of NCNP grant to Nakashima and a Japan Society for the Promotion of Science (JSPS) KAKENHI (JP22K15201) to Nakashima.
This publication includes data generated at the UC San Diego IGM Genomics Center utilizing an Illumina NovaSeq 6000 that was purchased with funding from an NIH SIG grant (No. S10 OD026929).
Disclosures: Muotri is a co-founder and has an equity interest in TISMOO, a company dedicated to genetic analysis and human brain organogenesis focusing on therapeutic applications customized for autism spectrum disorder and other neurological disorders with genetic origins.
The terms of this arrangement have been reviewed and approved by the University of California San Diego in accordance with its conflict-of-interest policies. The authors have a patent application in the works related to this publication.
About this autism and neuropharmacology research news
Author: Danielle Lewis
Source: UCSD
Contact: Danielle Lewis – UCSD
Image: The image is credited to Muotri Lab/ UC San Diego Health Sciences
Original Research: Open access.
“Human microglial cells as a therapeutic target in a neurodevelopmental disease model” by Pinar Mesci et al. Stem Cell Reports
Abstract
Human microglial cells as a therapeutic target in a neurodevelopmental disease model
Highlights
- MECP2 is implicated in microglial functions including phagocytosis
- Human microglia are implicated in synapse formation
- CD11b agonist ADH-503 restored phagocytosis and synaptic defects and increased survival
- Human microglia can be promising therapeutic targets for neurological conditions
Summary
Although microglia are macrophages of the central nervous system, their involvement is not limited to immune functions. The roles of microglia during development in humans remain poorly understood due to limited access to fetal tissue.
To understand how microglia can impact human neurodevelopment, the methyl-CpG binding protein 2 (MECP2) gene was knocked out in human microglia-like cells (MGLs). Disruption of the MECP2 in MGLs led to transcriptional and functional perturbations, including impaired phagocytosis.
The co-culture of healthy MGLs with MECP2-knockout (KO) neurons rescued synaptogenesis defects, suggesting a microglial role in synapse formation.
A targeted drug screening identified ADH-503, a CD11b agonist, restored phagocytosis and synapse formation in spheroid-MGL co-cultures, significantly improved disease progression, and increased survival in MeCP2-null mice.
These results unveil a MECP2-specific regulation of human microglial phagocytosis and identify a novel therapeutic treatment for MECP2-related conditions.
